Returning for the 10th year, Clinical Biomarkers and World CDx Boston is once again the home for the biomarker, translational, diagnostic and precision medicine community to enhance the translation and clinical validation of novel predictive biomarkers, and maximize access and adoption of Dx-enabled therapeutics.
Built for the entire precision medicine industry, from pharma and biotech to Dx, HCPs, regulators and payers, Clinical Biomarkers and World CDx Boston will cover end-to-end the translation, clinical implementation and commercialization of a biomarker strategy to increase market penetration and share. Ultimately, the meeting is here to turn biomarker RandD innovation into better utilization of Dx testing in healthcare – to provide patients with the right treatment decision and most effective therapies at the right time.
September 9th-12th, 2019
+1 617 455 4188
Drug Developer Conference Earlybird (Book by 05/31/19): USD 1599.0,
Drug Developer Conference (Standard rate): USD 2499.0,
Service Provider Conference Earlybird (Book by 05/31/19): USD 2299.0,
Service Provider Conference (Standard rate): USD 3199.0
Speakers: Emmanuelle di Tomaso (Bayer), Shirin Khambata Ford (Daiichi Sankyo), Michele Cleary (The Mark Foundation for Cancer Research), Jaya Goyal (Wave Life Sciences), Kate Haviland (Blueprint Medicines), Alice Walsh (Bristol-Myers Squibb)